Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Starpharma Holdings Ltd. (SPHRY : OTC)

• Company Description    Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia. Number of Employees: 50

• Price / Volume Information    Yesterday's Closing Price: $5.31 Daily Weekly Monthly 20 Day Moving Average: 934 shares Shares Outstanding: 40.74 (millions) Market Capitalization: $216.35 (millions) Beta: 1.71 52 Week High: $13.73 52 Week Low: $5.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.04% -4.32% 12 Week -22.76% -15.10% Year To Date -44.11% -28.30%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4-6 Southampton Crescent - Abbotsford,C3 3072 AUS ph: 61-3-8532-2700 fax: 61-3-9510-5955 investor.relations@starpharma.com http://www.starpharma.com

• General Corporate Information    Officers Jackie Fairley - Chief Executive Officer R B Thomas - Chairman Peter R Turvey - Director David McIntyre - Director Zita Peach - Director Peer Information Starpharma Holdings Ltd. (CORR.) Starpharma Holdings Ltd. (RSPI) Starpharma Holdings Ltd. (CGXP) Starpharma Holdings Ltd. (BGEN) Starpharma Holdings Ltd. (GTBP) Starpharma Holdings Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 855563102 SIC: 8731 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 40.74 Most Recent Split Date: (:1) Beta: 1.71 Market Capitalization: $216.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - - 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©